Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer
Abstract Objective Programmed death-1 (PD-1) inhibitors combined with chemotherapy show certain clinical benefits in advanced gastric cancer patients, but more evidence is still needed. The present study aimed to investigate the efficacy and safety of PD-1 inhibitors combined with chemotherapy in th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-04207-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226248703705088 |
|---|---|
| author | Xiaofei Cheng Yang Zhang Xingyuan Li Zhenning Xu Yaolin Chen |
| author_facet | Xiaofei Cheng Yang Zhang Xingyuan Li Zhenning Xu Yaolin Chen |
| author_sort | Xiaofei Cheng |
| collection | DOAJ |
| description | Abstract Objective Programmed death-1 (PD-1) inhibitors combined with chemotherapy show certain clinical benefits in advanced gastric cancer patients, but more evidence is still needed. The present study aimed to investigate the efficacy and safety of PD-1 inhibitors combined with chemotherapy in these patients. Methods Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 mg every 3 weeks) combined with chemotherapy were retrospectively enrolled. Data on treatment response, progression-free survival (PFS), and adverse reactions were collected. Results There were 1 (2.3%), 9 (20.9%), 32 (74.4%), and 1 (2.3%) patient who achieved complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate and disease control rate were 23.3% and 97.7%. The 1- and 2-year cumulative PFS rates were 63.3% and 19.8%. The median PFS (95% confidence interval) was 13.5 (10.7–16.3) months. Higher Eastern Cooperative Oncology Group performance status score (per score) [hazard ratio (HR) = 5.404, P = 0.047] and higher maximum diameter of the lesion (per cm) (HR = 1.860, P = 0.048) independently predicted shorter PFS. The adverse reactions included hemoglobin decreased (76.7%; grade 3: 16.3%), white blood cells decreased (74.4%; grade 3: 7.0%), blood platelet decreased (25.6%; grade 3: 2.3%), white blood cells increased (9.3%; grade 3: none), and reactive cutaneous capillary endothelial proliferation (23.3%; grade 3: 2.3%). Conclusion PD-1 inhibitors combined with chemotherapy may be an optional regimen for patients with advanced gastric cancer. However, the retrospective design and small sample size may limit the generalizability and robustness of our findings. |
| format | Article |
| id | doaj-art-ebea4730dbc74f0d8767b6cb47383345 |
| institution | Kabale University |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-ebea4730dbc74f0d8767b6cb473833452025-08-24T11:32:48ZengBMCBMC Gastroenterology1471-230X2025-08-012511810.1186/s12876-025-04207-0Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancerXiaofei Cheng0Yang Zhang1Xingyuan Li2Zhenning Xu3Yaolin Chen4Department of Oncology, Anqing 116 HospitalDepartment of Oncology, Anqing 116 HospitalDepartment of Oncology, Anqing 116 HospitalDepartment of Oncology, Anqing 116 HospitalDepartment of Oncology, Anqing 116 HospitalAbstract Objective Programmed death-1 (PD-1) inhibitors combined with chemotherapy show certain clinical benefits in advanced gastric cancer patients, but more evidence is still needed. The present study aimed to investigate the efficacy and safety of PD-1 inhibitors combined with chemotherapy in these patients. Methods Forty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 mg every 3 weeks) combined with chemotherapy were retrospectively enrolled. Data on treatment response, progression-free survival (PFS), and adverse reactions were collected. Results There were 1 (2.3%), 9 (20.9%), 32 (74.4%), and 1 (2.3%) patient who achieved complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate and disease control rate were 23.3% and 97.7%. The 1- and 2-year cumulative PFS rates were 63.3% and 19.8%. The median PFS (95% confidence interval) was 13.5 (10.7–16.3) months. Higher Eastern Cooperative Oncology Group performance status score (per score) [hazard ratio (HR) = 5.404, P = 0.047] and higher maximum diameter of the lesion (per cm) (HR = 1.860, P = 0.048) independently predicted shorter PFS. The adverse reactions included hemoglobin decreased (76.7%; grade 3: 16.3%), white blood cells decreased (74.4%; grade 3: 7.0%), blood platelet decreased (25.6%; grade 3: 2.3%), white blood cells increased (9.3%; grade 3: none), and reactive cutaneous capillary endothelial proliferation (23.3%; grade 3: 2.3%). Conclusion PD-1 inhibitors combined with chemotherapy may be an optional regimen for patients with advanced gastric cancer. However, the retrospective design and small sample size may limit the generalizability and robustness of our findings.https://doi.org/10.1186/s12876-025-04207-0Programmed death-1 inhibitors combined with chemotherapyAdvanced gastric cancerTreatment responseProgression-free survivalAdverse reactions |
| spellingShingle | Xiaofei Cheng Yang Zhang Xingyuan Li Zhenning Xu Yaolin Chen Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer BMC Gastroenterology Programmed death-1 inhibitors combined with chemotherapy Advanced gastric cancer Treatment response Progression-free survival Adverse reactions |
| title | Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| title_full | Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| title_fullStr | Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| title_full_unstemmed | Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| title_short | Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| title_sort | efficacy and safety of programmed death 1 inhibitors combined with chemotherapy in patients with advanced gastric cancer |
| topic | Programmed death-1 inhibitors combined with chemotherapy Advanced gastric cancer Treatment response Progression-free survival Adverse reactions |
| url | https://doi.org/10.1186/s12876-025-04207-0 |
| work_keys_str_mv | AT xiaofeicheng efficacyandsafetyofprogrammeddeath1inhibitorscombinedwithchemotherapyinpatientswithadvancedgastriccancer AT yangzhang efficacyandsafetyofprogrammeddeath1inhibitorscombinedwithchemotherapyinpatientswithadvancedgastriccancer AT xingyuanli efficacyandsafetyofprogrammeddeath1inhibitorscombinedwithchemotherapyinpatientswithadvancedgastriccancer AT zhenningxu efficacyandsafetyofprogrammeddeath1inhibitorscombinedwithchemotherapyinpatientswithadvancedgastriccancer AT yaolinchen efficacyandsafetyofprogrammeddeath1inhibitorscombinedwithchemotherapyinpatientswithadvancedgastriccancer |